InVitria Exhibits at 22nd Annual European Society for Animal Cell Technology (ESACT) Conference


InVitria sees strong demand for robust, animal component-free cell culture systems that not only meet regulatory guidelines, but also deliver consistency and performance.


Fort Collins, CO May 12, 2011 – InVitria announces its attendance at the 22nd Annual European Society for Animal Cell Technology (ESACT) Conference in Vienna, Austria, May 15-18. The ESACT conference is one of the largest cell culture conferences in the world, bringing together leading academia and industry scientists to advance cell-based technologies.

InVitria will be representing its line of animal component-free cell culture media products that improve productivity, increase safety, and reduce the costs of cell culture production. These products are effective in many cell lines, such as CHO, hybridoma, HEK293, VERO, MDCK, and stem cells.

“InVitria’s products address three main concerns facing cell culture systems today: improving productivity, enhancing consistency, and removing animal and undefined components from media,” said Shawn Smith, Vice President of Sales and Marketing for InVitria. “These concerns can now be overcome in a cost-effective manner by using products from InVitria.”

InVitria will be exhibiting in booth number 227 at ESACT. InVitria encourages attendees to stop by its booth to learn more about its products and how they can help cell culture scientists and process developers achieve their objectives.

About InVitria (www.InVitria.com)

InVitria develops, manufactures, and markets a portfolio of products used in cell culture, diagnostics, and bioproduction. InVitria’s products address customer needs for defined, animal component-free cell culture supplements in stem cell technology, regenerative medicine, biomanufacturing, diagnostics, biopharmaceutical formulation, cell-based vaccines, and general life science research.

To obtain more information about InVitria’s product solutions, e-mail This e-mail address is being protected from spambots. You need JavaScript enabled to view it This e-mail address is being protected from spambots. You need JavaScript enabled to view it , visit us online at www.InVitria.com , or call toll-free 1-800-916-8311.

###
 
  • Blog: The Cell Culture Dish

    Cell Culture Media supplement Blog Strategies for Improving Viral Yield in Vaccine Manufacturing

    A recent article in Pharma Times titled "US biopharma: nearly 300 vaccines in R&D," points out that there are currently 300 vaccines either in clinical studies or under review by the Food and Drug Administration (FDA). While not all vaccines are cell culture derived vaccines, it does indicate that a large number of cell culture based viral vaccines are in the pipeline and that perhaps viral vaccine manufacturing should be examined. One area under consideration is how to improve viral yield so that vaccines can be made at lower cost ... Read More

  • Latest News

    Invitria Cell Culture Media News InVitria Attends the 13th Bi-Annual Cell Culture Engineering Conference

    March 29, 2012 - InVitria is attending the 13th Bi-Annual Cell Culture Engineering Conference in Scottsdale, Arizona April 22nd through the 27th. This event is an invitation only conference that includes approximately 350 of the world's top academic and industry cell culture scientists. Topics at the conference range from fundamental science to the engineering challenges of cell culture process development.... read more